{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:41:51Z","timestamp":1789807311410,"version":"4.0.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CRISPR technologies have advanced cancer modelling in mice, but CRISPR activation (CRISPRa) methods have not been exploited in this context. We establish a CRISPRa mouse (\n                    <jats:italic>dCas9a-SAM<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>KI<\/jats:italic>\n                    <\/jats:sup>\n                    ) for inducing gene expression in vivo and in vitro. Using\n                    <jats:italic>dCas9a-SAM<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>KI<\/jats:italic>\n                    <\/jats:sup>\n                    primary lymphocytes, we induce B cell restricted genes in T cells and vice versa, demonstrating the power of this system. There are limited models of aggressive double hit lymphoma. Therefore, we transactivate pro-survival BCL-2 in\n                    <jats:italic>E\u00b5-Myc<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>T\/+<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>;dCas9a-SAM<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>KI\/+<\/jats:italic>\n                    <\/jats:sup>\n                    haematopoietic stem and progenitor cells. Mice transplanted with these cells rapidly develop lymphomas expressing high BCL-2 and MYC. Unlike standard\n                    <jats:italic>E\u00b5-Myc<\/jats:italic>\n                    lymphomas, BCL-2 expressing lymphomas are highly sensitive to the BCL-2 inhibitor venetoclax. We perform genome-wide activation screens in these lymphoma cells and find a dominant role for the BCL-2 protein A1 in venetoclax resistance. Here we show the potential of our CRISPRa model for mimicking disease and providing insights into resistance mechanisms towards targeted therapies.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-32485-9","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:08:01Z","timestamp":1660302481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance"],"prefix":"10.1038","volume":"13","author":[{"given":"Yexuan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Diepstraten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-9683","authenticated-orcid":false,"given":"Margaret A.","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6knur","family":"Giner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-3291","authenticated-orcid":false,"given":"Stephanie","family":"Trezise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-0879","authenticated-orcid":false,"given":"Ashley P.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena R.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2981-9282","authenticated-orcid":false,"given":"Amali","family":"Cooray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0800-8472","authenticated-orcid":false,"given":"Kira","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Heidersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Kueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1563-5426","authenticated-orcid":false,"given":"Martin","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-6977","authenticated-orcid":false,"given":"Jane E.","family":"Visvader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-6637","authenticated-orcid":false,"given":"Stephen L.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-4891","authenticated-orcid":false,"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-1938","authenticated-orcid":false,"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1201","authenticated-orcid":false,"given":"Gemma L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-7581","authenticated-orcid":false,"given":"Marco J.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"32485_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR-Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490\u2013507 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"32485_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-313X.1997.11030605.x","volume":"11","author":"T Aoyama","year":"1997","unstructured":"Aoyama, T. & Chua, N. H. A glucocorticoid-mediated transcriptional induction system in transgenic plants. Plant J. 11, 605\u2013612 (1997).","journal-title":"Plant J."},{"key":"32485_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nmeth.2598","volume":"10","author":"ML Maeder","year":"2013","unstructured":"Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977\u2013979 (2013).","journal-title":"Nat. Methods"},{"key":"32485_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nbt.2675","volume":"31","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833\u2013838 (2013).","journal-title":"Nat. Biotechnol."},{"key":"32485_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nmeth.2600","volume":"10","author":"P Perez-Pinera","year":"2013","unstructured":"Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9\u2013based transcription factors. Nat. Methods 10, 973\u2013976 (2013).","journal-title":"Nat. Methods"},{"key":"32485_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442\u2013451 (2013).","journal-title":"Cell"},{"key":"32485_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nmeth.3312","volume":"12","author":"A Chavez","year":"2015","unstructured":"Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326\u2013328 (2015).","journal-title":"Nat. Methods"},{"key":"32485_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert, L. A. et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159, 647\u2013661 (2014).","journal-title":"Cell"},{"key":"32485_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583\u2013588 (2015).","journal-title":"Nature"},{"key":"32485_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","volume":"159","author":"E Tanenbaum Marvin","year":"2014","unstructured":"Tanenbaum Marvin, E. et al. A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging. Cell 159, 635\u2013646 (2014).","journal-title":"Cell"},{"key":"32485_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-cancerbio-030617-050455","volume":"2","author":"A Ventura","year":"2018","unstructured":"Ventura, A. & Dow, L. E. Modeling Cancer in the CRISPR Era. Annu. Rev. Cancer Biol. 2, 111\u2013131 (2018).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"32485_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"32485_CR13","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/eji.202048712","volume":"50","author":"MA Potts","year":"2020","unstructured":"Potts, M. A., McDonald, J. A., Sutherland, K. D. & Herold, M. J. Critical cancer vulnerabilities identified by unbiased CRISPR\/Cas9 screens inform on efficient cancer Immunotherapy. Eur. J. Immunol. 50, 1871\u20131884 (2020).","journal-title":"Eur. J. Immunol."},{"key":"32485_CR14","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","volume":"117","author":"SM Aukema","year":"2011","unstructured":"Aukema, S. M. et al. Double-hit B-cell lymphomas. Blood 117, 2319\u20132331 (2011).","journal-title":"Blood"},{"key":"32485_CR15","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","volume":"114","author":"NA Johnson","year":"2009","unstructured":"Johnson, N. A. et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114, 2273\u20132279 (2009).","journal-title":"Blood"},{"key":"32485_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Azizian, N. G., Dou, Y., Pham, L. V. & Li, Y. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J. Hematol. Oncol. 12, 119 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"32485_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/onc.2012.117","volume":"32","author":"I Leskov","year":"2013","unstructured":"Leskov, I. et al. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene 32, 1066\u20131072 (2013).","journal-title":"Oncogene"},{"key":"32485_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2013.12.041","volume":"156","author":"CP Pallasch","year":"2014","unstructured":"Pallasch, C. P. et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156, 590\u2013602 (2014).","journal-title":"Cell"},{"key":"32485_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/348331a0","volume":"348","author":"A Strasser","year":"1990","unstructured":"Strasser, A., Harris, A. W., Bath, M. L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331\u2013333 (1990).","journal-title":"Nature"},{"key":"32485_CR20","doi-asserted-by":"crossref","unstructured":"Rav\u00e0 M, et al. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC\/BCL2 double-hit B cell lymphoma. Sci Transl Med 10, (2018).","DOI":"10.1126\/scitranslmed.aan8723"},{"key":"32485_CR21","doi-asserted-by":"crossref","unstructured":"Chen B-J, Fend F, Campo E, Quintanilla-Martinez L. Aggressive B-cell lymphomas\u2014from morphology to molecular pathogenesis. Annals of Lymphoma 3, (2019).","DOI":"10.21037\/aol.2018.12.02"},{"key":"32485_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino, D. et al. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell 34, 879\u2013891 (2018).","journal-title":"Cancer Cell"},{"key":"32485_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze, R. et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36, 369\u2013384.e313 (2019).","journal-title":"Cancer Cell"},{"key":"32485_CR24","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen, R. et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood 137, 2721\u20132735 (2021).","journal-title":"Blood"},{"key":"32485_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/science.1067081","volume":"295","author":"C Lois","year":"2002","unstructured":"Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868\u2013872 (2002).","journal-title":"Science"},{"key":"32485_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533\u2013538 (1985).","journal-title":"Nature"},{"key":"32485_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","volume":"10","author":"BJ Aubrey","year":"2015","unstructured":"Aubrey, B. J. et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 10, 1422\u20131432 (2015).","journal-title":"Cell Rep."},{"key":"32485_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1101\/gad.232009.113","volume":"28","author":"GL Kelly","year":"2014","unstructured":"Kelly, G. L. et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28, 58\u201370 (2014).","journal-title":"Genes Dev."},{"key":"32485_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"32485_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.1141229","volume":"316","author":"TH Thai","year":"2007","unstructured":"Thai, T. H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604\u2013608 (2007).","journal-title":"Science"},{"key":"32485_CR31","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.celrep.2019.10.097","volume":"29","author":"MSY Low","year":"2019","unstructured":"Low, M. S. Y. et al. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis. Cell Rep. 29, 2634\u20132645.e2635 (2019).","journal-title":"Cell Rep."},{"key":"32485_CR32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/cdd.2008.195","volume":"16","author":"EM Michalak","year":"2009","unstructured":"Michalak, E. M. et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 16, 684\u2013696 (2009).","journal-title":"Cell Death Differ."},{"key":"32485_CR33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848 (2004).","journal-title":"Science"},{"key":"32485_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/10428194.2014.907896","volume":"56","author":"N Gebauer","year":"2015","unstructured":"Gebauer, N. et al. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk. Lymphoma 56, 179\u2013185 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"32485_CR35","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1002\/j.1460-2075.1995.tb00304.x","volume":"14","author":"A Strasser","year":"1995","unstructured":"Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H. & Cory, S. Bcl-2 and Fas\/APO-1 regulate distinct pathways to lymphocyte apoptosis. Embo j. 14, 6136\u20136147 (1995).","journal-title":"Embo j."},{"key":"32485_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16828-y","volume":"11","author":"AP Ng","year":"2020","unstructured":"Ng, A. P. et al. An Erg-driven transcriptional program controls B cell lymphopoiesis. Nat. Commun. 11, 3013 (2020).","journal-title":"Nat. Commun."},{"key":"32485_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-022-01249-9","volume":"15","author":"Y Zhuang","year":"2022","unstructured":"Zhuang, Y. et al. Altered pathways and targeted therapy in double hit lymphoma. J. Hematol. Oncol. 15, 26 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"32485_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky, A. et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J. Hematol. Oncol. 13, 173 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"32485_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"32485_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3950","volume":"15","author":"FJ S\u00e1nchez-Rivera","year":"2015","unstructured":"S\u00e1nchez-Rivera, F. J. & Jacks, T. Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 15, 387\u2013395 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"32485_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nmeth.3871","volume":"13","author":"A Chavez","year":"2016","unstructured":"Chavez, A. et al. Comparison of Cas9 activators in multiple species. Nat. Methods 13, 563\u2013567 (2016).","journal-title":"Nat. Methods"},{"key":"32485_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22932-4","volume":"12","author":"C Hunt","year":"2021","unstructured":"Hunt, C. et al. Tissue-specific activation of gene expression by the Synergistic Activation Mediator (SAM) CRISPRa system in mice. Nat. Commun. 12, 2770 (2021).","journal-title":"Nat. Commun."},{"key":"32485_CR43","doi-asserted-by":"publisher","first-page":"e10611","DOI":"10.1371\/journal.pone.0010611","volume":"5","author":"JY Qin","year":"2010","unstructured":"Qin, J. Y. et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5, e10611 (2010).","journal-title":"PLoS One"},{"key":"32485_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41593-017-0060-6","volume":"21","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat. Neurosci. 21, 440\u2013446 (2018).","journal-title":"Nat. Neurosci."},{"key":"32485_CR45","doi-asserted-by":"crossref","unstructured":"Matharu N, et al. CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science 363, (2019).","DOI":"10.1126\/science.aau0629"},{"key":"32485_CR46","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","volume":"18","author":"MP Gemberling","year":"2021","unstructured":"Gemberling, M. P. et al. Transgenic mice for in vivo epigenome editing with CRISPR-based systems. Nat. Methods 18, 965\u2013974 (2021).","journal-title":"Nat. Methods"},{"key":"32485_CR47","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg, J. W. How I treat double-hit lymphoma. Blood 130, 590\u2013596 (2017).","journal-title":"Blood"},{"key":"32485_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07198-1","volume":"20","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma. BMC Cancer 20, 714 (2020).","journal-title":"BMC Cancer"},{"key":"32485_CR49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3324\/haematol.2018.204958","volume":"104","author":"A Uchida","year":"2019","unstructured":"Uchida, A. et al. Targeting BCL2 with venetoclax is a promising therapeutic strategy for \u201cdouble-proteinexpression\u201d lymphoma with MYC and BCL2 rearrangements. Haematologica 104, 1417\u20131421 (2019).","journal-title":"Haematologica"},{"key":"32485_CR50","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S. et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J. Clin. Oncol. 35, 826\u2013833 (2017).","journal-title":"J. Clin. Oncol."},{"key":"32485_CR51","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","volume":"33","author":"DM Moujalled","year":"2019","unstructured":"Moujalled, D. M. et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 33, 905\u2013917 (2019).","journal-title":"Leukemia"},{"key":"32485_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med"},{"key":"32485_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"32485_CR54","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1182\/blood.2020008528","volume":"137","author":"S Boiko","year":"2021","unstructured":"Boiko, S. et al. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood 137, 2947\u20132957 (2021).","journal-title":"Blood"},{"key":"32485_CR55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/cdd.2016.156","volume":"24","author":"RL Schenk","year":"2017","unstructured":"Schenk, R. L. et al. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ. 24, 534\u2013545 (2017).","journal-title":"Cell Death Differ."},{"key":"32485_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/cdd.2016.155","volume":"24","author":"S Tuzlak","year":"2017","unstructured":"Tuzlak, S. et al. The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection. Cell Death Differ. 24, 523\u2013533 (2017).","journal-title":"Cell Death Differ."},{"key":"32485_CR57","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/cdd.2017.122","volume":"24","author":"AJ Kueh","year":"2017","unstructured":"Kueh, A. J. et al. An update on using CRISPR\/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles. Cell Death Differ. 24, 1821\u20131822 (2017).","journal-title":"Cell Death Differ."},{"key":"32485_CR58","doi-asserted-by":"publisher","first-page":"18507","DOI":"10.1073\/pnas.0806213105","volume":"105","author":"MJ Herold","year":"2008","unstructured":"Herold, M. J., van den Brandt, J., Seibler, J. & Reichardt, H. M. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc. Natl Acad. Sci. USA 105, 18507\u201318512 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32485_CR59","first-page":"95","volume":"3","author":"Z Dai","year":"2014","unstructured":"Dai, Z. et al. edgeR: a versatile tool for the analysis of shRNA-seq and CRISPR-Cas9 genetic screens. F1000Res 3, 95 (2014).","journal-title":"F1000Res"},{"key":"32485_CR60","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1093\/nar\/gks042","volume":"40","author":"DJ McCarthy","year":"2012","unstructured":"McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 40, 4288\u20134297 (2012).","journal-title":"Nucleic Acids Res"},{"key":"32485_CR61","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015).","journal-title":"Nucleic Acids Res"},{"key":"32485_CR62","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkz114","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res 47, e47 (2019).","journal-title":"Nucleic Acids Res"},{"key":"32485_CR63","first-page":"1438","volume":"5","author":"Y Chen","year":"2016","unstructured":"Chen, Y., Lun, A. T. & Smyth, G. K. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Res 5, 1438 (2016).","journal-title":"F1000Res"},{"key":"32485_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"32485_CR65","doi-asserted-by":"crossref","unstructured":"Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3 (2004).","DOI":"10.2202\/1544-6115.1027"},{"key":"32485_CR66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc.: Ser. B (Methodol.) 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc.: Ser. B (Methodol.)"},{"key":"32485_CR67","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32485_CR68","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1093\/nar\/gks461","volume":"40","author":"D Wu","year":"2012","unstructured":"Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 40, e133 (2012).","journal-title":"Nucleic Acids Res"},{"key":"32485_CR69","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"32485_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-94","volume":"11","author":"JH Bullard","year":"2010","unstructured":"Bullard, J. H., Purdom, E., Hansen, K. D. & Dudoit, S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinforma. 11, 94 (2010).","journal-title":"BMC Bioinforma."},{"key":"32485_CR71","doi-asserted-by":"publisher","unstructured":"Deng Y, et al. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. GitHub, https:\/\/doi.org\/10.5281\/zenodo.6816211 (2022).","DOI":"10.5281\/zenodo.6816211"}],"updated-by":[{"DOI":"10.1038\/s41467-022-32817-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32485-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T06:31:16Z","timestamp":1727764276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32485-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32485"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32485-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-856034\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"29 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-022-32817-9","URL":"https:\/\/doi.org\/10.1038\/s41467-022-32817-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Walter and Eliza Hall Institute receives milestone and royalty payments related to venetoclax. A.S. is consulting for Genentech and Servier. A.H. and B.H. are employees of Genentech, Inc. and shareholders of Roche. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4739"}}